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We investigated the ability of the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) to interact with gemcitabine (GEM) in inducing
pancreatic cancer cell death. The combined treatment with TSA and GEM synergistically inhibited growth of four pancreatic adenocarcinoma cell
lines and induced apoptosis. This effect was associated with the induction of reactive oxygen species (ROS) by GEM, increased expression of the
pro-apoptotic BIM gene by both TSA and GEM and downregulation of the 5′-nucleotidase UMPH type II gene by TSA. The expression of other
genes critical for GEM resistance (nucleoside transporters, deoxycytidine kinase, cytidine deaminase, and ribonucleotide reductase genes) was not
affected by TSA. The functional role of ROS in cell growth inhibition by GEM was supported by (i) a significantly reduced GEM-associated
growth inhibition by the free radical scavenger N-acetyl-L-cysteine, and (ii) a positive correlation between the basal level of ROS and sensitivity to
GEM in 10 pancreatic cancer cell lines. The functional role of both Bim and 5′-nucleotidase UMPH type II in cell growth inhibition by TSA and
GEM was assessed by RNA interference assays. In vivo studies on xenografts of pancreatic adenocarcinoma cells in nude mice showed that the
association of TSA and GEM reduced to 50% the tumour mass and did not cause any apparent form of toxicity, while treatments with TSA or
GEM alone were ineffective. In conclusion, the present study demonstrates a potent anti-tumour activity of TSA/GEM combination against
pancreatic cancer cells in vitro and in vivo, strongly supporting the use of GEM in combination with an HDAC inhibitor for pancreatic cancer
therapy.
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doi:10.1016/j.bbamcr.2007.05.002survival lower than 5% [1]; at diagnosis, less than 20% of patients
are candidates for surgery with curative intent [2]. Standard
treatments for advanced disease include radiotherapy and/or
chemotherapy regimens. Radiotherapy has been shown to have
some utility for regional confined cancers, but is often too toxic for
tissues surrounding the neoplasia. Widely used chemotherapeutic
regimes include 5-fluorouracil (5-FU) and gemcitabine, a nucleo-
side analogue of cytidine (2′,2′-difluorodeoxycytidine; dFdC)
(GEM) [3]. However, even GEM, which is now considered the
gold standard, has a response rate of less than 20%, although it does
provide an improvement in the quality of life [4].
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described, such as inefficient cellular uptake due to low
expression of nucleoside transporters (NTs) [5], reduced levels
of the activating enzyme deoxycytidine kinase (dCK) [6] and
increased cytidine deaminase (CDD) [7] or cytoplasmic 5′
nucleotidase (5NT) activities, which lead to GEM inactivation
[6–8] and loss of sensitivity of ribonucleotide reductase
(RNR) to GEM inhibition [9]. p53, the guardian of genome
integrity that typically induces the apoptotic response of cells
to DNA damaging drugs, is also involved in the resistance to
GEM [10]. Indeed, pancreatic cancer cells, which present a
high rate of mutations of the TP53 gene [11], have been
shown to strongly increase GEM sensitivity after reintroduc-
tion of the wild type TP53 gene in vitro and in vivo [12,13].
Recently, it has been reported that an increased expression of
selenoprotein P, which suppress the intracellular free radicals,
determines resistance to GEM, strongly suggesting that the
oxidative stress could be a novel mechanism of GEM action
[14].
Among multiple genetic and cytogenetic alterations that
characterize human tumours, great emphasis was recently given
to epigenetic events, such as DNA methylation or histone
acetylation [15]. Alterations in histone acetyl transferase (HAT)
or histone deacetylase (HDAC) activity occur in numerous
cancers and have prompted the search for pharmacological
agents capable of inhibiting these enzymes [16]. HDAC
inhibitors seem to be specifically selective against tumour
cells [17,18] and show a very low toxicity in vivo [19,20].
Trichostatin A (TSA) is one of the natural inhibitors of HDAC
that promotes histone hyperacetylation and strongly induce
apoptosis, by altering the expression of some apoptotic genes
[21–25].
We have previously shown that TSA induces apoptosis
and G2-phase cell cycle arrest in TP53 mutated pancreatic
cancer cell lines [23]. Moreover, we have reported that
TSA enhances the response of a panel of five chemother-
apeutic drugs on ten pancreatic adenocarcinoma cell lines
and that it is the best partner for the gold standard GEM
[26].
Here, we have characterized the mechanisms responsible
for pancreatic cancer cell growth inhibition by TSA and GEM,
both in vitro and in vivo, and analyzed whether TSA affects
the molecular events implicated in GEM resistance. Our
results demonstrate that TSA synergistically increases GEM-
induced cell growth inhibition of four pancreatic adenocarci-
noma cell lines, all with mutations in the TP53 gene [11]. This
synergistic effect depends on apoptosis, but not cell cycle
arrest induction, and is strictly related to (i) the activation of
the oxidative stress by GEM; (ii) the repression of the 5′-
nucleotidase UMPH type II gene by TSA; (iii) the enhance-
ment of the proapoptotic BIM expression by TSA and GEM.
We also report that the sensitivity to GEM in 10 pancreatic
adenocarcinoma cell lines is related to the intrinsic ROS stress.
Finally, we show that the combined treatment with TSA and
GEM significantly inhibits subcutaneous growth of human
pancreatic adenocarcinoma in nude mice, whereas single
treatments have no effect.2. Materials and methods
2.1. Chemicals
Trichostatin A (TSA) was obtained from Sigma-Aldrich Company Ltd.,
solubilised in DMSO and stored at −80 °C until use. Gemcitabine (GEM;
Gemzar, Lilly) and N-acetyl-L-cysteine (NAC) (Sigma) were freshly prepared in
sterile water.
2.2. Cell culture
Ten human pancreatic cancer cell lines were used, comprising seven cell
lines derived from primary cancer (MiaPaca2, PaCa3, PaCa44, PANC1,
PT45P1, PSN1, and PC) and three from metastatic cancers (HPAF II,
CFPAC1, and T3M4) (see [11] for genetic characterization and primary tissue
source). All cell lines were grown in RPMI 1640 supplemented with 20 mM
glutamine, 10% FBS and 50 μg/ml gentamicin sulfate (BioWhittaker, Italy) and
were incubated at 37 °C with 5% CO2.
2.3. Cell proliferation assay
Cells were plated in 96-well cell culture plates (4×103 cells/well) and were
treated with TSA and/or GEM at the indicated concentrations. Treated cells were
maintained at 37 °C in 5% CO2 for times indicated in the legends to the figures,
then stained with Crystal Violet (Sigma). The dye was solubilised in 1% SDS in
PBS and measured photometrically (A595 nm) to determine cell viability. Three
independent experiments were performed for each assay condition.
2.4. Drug combination studies
The combination index (CI) was calculated by the Chou–Talalay equation,
which takes into account both the potency (Dm or IC50) and the shape of the
dose–effect curve [27,28], taking advantage of the CalcuSyn software (Biosoft,
Cambridge, UK). The general equation for the classic isobologram (CI=1) is
given by CI=(D)1/(Dx)1+(D)2/(Dx)2+ [(Dx)1 · (Dx)2]/[(D)1+ (D)2], where (Dx)1
and (Dx)2 in the denominators are the doses (or concentrations) for D1 (drug 1)
and D2 (drug 2) alone that gives x% inhibition, whereas (D)1 and (D)2 in the
numerators are the doses of drug 1 and drug 2 in combination that also inhibited
x% (i.e., isoeffective). CIb1, CI=1, or CIN1 generally indicated synergistic,
additive, or antagonistic effect, respectively. However, we decided to use a cut
off for the CI of 0.8, and identified a synergistic effect when CIs were smaller
than 0.8, an antagonistic effect when they were greater than 1.2, and an additive
effect when they were between 0.8 and 1.2. The linear correlation coefficient (r)
of the median–effect plot is considered the first line of statistics to measure the
conformity of the data with the mass–action law principle when the
experimental measurement is assumed to be accurate. A r value equal to 1
indicates perfect conformity. A poor r value may be the result of biological
variability or experimental deviations. For tissue culture systems a minimum r
value of 0.90 should be obtained in order to consider the experiment valid.
Throughout all the experiments we obtained a mean of r=0.95±0.01. Dose
reduction index (DRI) represents the measure of how much the dose of each
drug in a synergistic combination may be reduced at a given effect level
compared with the doses of each drug alone. Treatment interaction effects
between TSA and GEM were assessed at a concentration ratio 1:1. CI/fractional
effect curves represent the CI versus the fraction of cells affected/killed by TSA
and GEM in combination. The fractional effect is the % of growth inhibition
corresponding to a given combination of the two drugs.
2.5. Cell cycle analysis
Cell cycle distribution was analyzed using propidium iodide (PI)-stained
cells. Briefly, 106 cells were washed with PBS, incubated with 0.1% sodium
citrate dihydrate, 0.1% Triton X-100, 200 μg/ml RNase A, 50 μg/ml propidium
iodide (Roche Molecular Biochemicals) and analyzed using a flow cytometer
(Becton Dickinson). The percentage of cells in the different stages of the cell
cycle was determined using the ModFitLT software program.
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The percentage of apoptotic cells was evaluated by staining 2×105 cells
with annexin V-FITC (Bender Med System, Vienna, Austria) and 5 mg/ml
propidium iodide in binding buffer [10 mM HEPES/NaOH (pH 7.4), 140 mM
NaOH, and 2.5 mM CaCl2] for 10 min at room temperature in the dark. The
samples were analyzed by flow cytometry (FACScalibur, Becton-Dickinson)
within 1 h to determine the percentage of cells displaying annexin V+/
propidium iodide-(early apoptosis) or annexin V+/propidium iodide+ staining
(late apoptosis). Three independent experiments were performed for each
assay condition.
Caspase-3 activity was assayed as previously reported [23]. Briefly, after
treatment with TSA, cells were washed twice with ice-cold PBS and lysed
by freeze and thawing in caspase buffer (100 mM HEPES, 200 mM NaCl,
1 mM EDTA, 20 mM CHAPS, 10% sucrose). Hundred μg of total protein
extract were incubated with 10 μg of the fluorogenic peptide substrate Ac-
DEVD-AFC (PharMingen, San Diego, CA) 10 min at 30 °C and the release
of 7-amino-4-methylcoumarin was determined fluorometrically using an
excitation wavelength of 380 nm and an emission wavelength of 460 nm.
Morphological changes of the cells were analyzed by staining with H&E.
Cells treated with TSA and/or GEM presented features typical of apoptotic
cells (data not shown).
2.7. Analysis of mitochondrial membrane potential (ΔΨm)
2×105 cells were stained with 40 nM 3,3-dihexyloxacarbocyanine
(Molecular Probes) at 37 °C for 20 min, washed twice in PBS and then analyzed
by flow cytometry. The percentage of cells exhibiting a decreased level of 3,3-
dihexyloxacarbocyanine uptake that reflects loss of ΔΨm, was determined by
flow cytometry.
2.8. Measurement of reactive oxygen species (ROS) production
The non-fluorescent 2′,7′-dichlorofluorescin (DCF) probe, which becomes
highly fluorescent on reaction with ROS, was used to evaluate cellular ROSFig. 1. Effect of TSA (♦) or GEM (○) treatment on growth of four pancreatic adenoc
TSA or GEM were added at the indicated concentrations and cells were further incu
experiments for each drug concentration. Cell proliferation was determined using thproduction [29]. Briefly, 2×105 cells were incubated with 10 μM DCF (Sigma)
at 37 °C for 15 min and then analyzed by flow cytometry.
2.9. Small interfering RNA
Cells were plated in 96-well for proliferation assays (4×103 cells/well) or
into 60 mm cell culture plates at 2.5×105 cells/plate for RNA extraction.
After 24 h, growth medium was removed and fresh serum/antibiotics free
medium was added. Cells (at ∼30% confluency) were transfected with
siRNA at a final concentration of 100 nM using jetSI-ENDO-Fluo cationic
transfection reagent (Polyplus transfection, TEMA Ricerche, Italy) according
to the manufacturer's transfection protocol. Silencing was performed by
SMARTpool siRNAs (BIM: human BCL2L11, NM_006538; UMPH type II:
human NT5C, NM_014595) purchased from Dharmacon (Tema Ricerche,
Italy). A negative control designed to minimize targeting to any known
human genes (siCONTROL Non-targeting siRNA pool, Dharmacon) was
transfected to validate transfection results. Twenty-four hours after transfec-
tion TSA and/or GEM were added and cells were further incubated for 24 h
before analysis. Transfection efficiency was assessed by cytofluorimetric
analysis and ranged between 88 and 96%.
2.10. Immunoblot analysis
Protein extracts from 106 cells, untreated or treated with TSA, and from
tumour mass, removed from both control and treated animal groups, were
prepared in acid buffer (0.2 M Tris, 0.2 M HCl, 1 mM phenylmethylsulfonyl
fluoride, 1% β-mercaptoethanol, 1× protease inhibitor cocktail) by freeze and
thawing, and the lysate was clarified by centrifugation. Five μg of protein
extracts were electrophoresed and blotted onto PVDF membranes (Millipore,
Bedford, MA). Membranes were probed with anti-acetyl-Histone H4 polyclonal
Ab (Upstate Biotechnology) or anti-human α-Tubulin mAb (Oncogene).
Horseradish peroxidase conjugated anti-mouse IgG (Upstate Biotechnology)
was used to detect specific proteins. Immunodetection was carried out using the
chemiluminescent substrates (Pierce) and recorded by using a HyperfilmECL
(Amersham Pharmacia Biotech).arcinoma cell lines. Cells were seeded in 96-well plates and incubated overnight.
bated for 48 h. Values are the means of triplicate wells from three independent
e crystal violet colorimetric assay. ***pb0.001.
Fig. 2. CI /fractional effect curves for CFPAC, PANC1, PC, and T3M4 cells. A 1:1 molar ratio of TSA and GEM have been evaluated as described in Materials and
methods. The figure shows the fractional effects vs. the different CIs. The fractional effect is the % of growth inhibition given by each combination of the two drugs.
This value is represented on the X axis of the curve. CI values obtained by the same combinations are reported on the Y axis. When CI is below 0.8 a synergistic
condition is recorded; with CI below 0.5 and between 0.8 and 1.0 a strong synergism or additivity, respectively, is found. The statistical significance of each point was
evaluated with ANOVA and the derived p values were always less than 0.01.
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Total cellular RNAwas prepared from 5×106 cells and reverse transcribed as
previously described [23]. The thermal cycler protocols and specific primers are
the followings: BIM 5′-TGATATCAATGCATTCTCCACACCAGGCGGAC-3′
and 5′-AGAATTCATGGCAAAGCAACCTTCTGATGTAAG-3′, 94 °C (30 s),
56 °C (30 s), 72 °C (30 s), 30 cycles; UMPH type II 5′-ATGAACGACCTACCG-
GACAC-3′ and 5′-CGGTAGCACAGCGCTTAACG-3′, 94 °C (30 s), 58 °CTable 1
Dose Reduction Index (DRI) a and Combination Index (CI) b values of TSA/GEM c
Cell lines Molar ratio 1:1
TSA/GEM
ED50 (nM) ED75 (nM) CI50 (±SEM)
T3m4 21.9 37.2 0.8 (0.17)
PANCI 79.8 193.1 0.4 (0.05)
PC 42.7 103.8 0.6 (0.042)
CFPAC1 11.9 32 1.0 (0.123)
(DRI50) and IC75 (DRI75) in combination setting compared with each drug alone. 1:1
and N1 indicate synergy, additivity, and antagonism, respectively.
a DRI values (mean±Standard Error of the Mean (SEM) from at least three separ
(fold) of dose reduction obtained for IC50.
b CI values (mean±Standard Error of the Mean (SEM) from at least three separate
induced by drug interaction when 50% (CI50) or 75% (CI75) growth inhibition is r(30 s), 72 °C (1 min), 30 cycles; β-ACTIN 5′-ACCAACTGGGACGACATGGA-
GAA-3′ and 5′-GTGGTGGTGAAGCTGTAGCC-3′, 94 °C (1 min), 55 °C
(1 min), 72 °C (1 min), 25 cycles. PCR products were separated by electrophoresis
and the bands were photographed and scanned as digital peaks. The areas of the
peaks were calculated in arbitrary units using the public domain NIH Image
program (developed at the U.S. National Institutes of Health and available on the
Internet at http://rsb.info.nih.gov/nih-image/). β-ACTIN was used as an internal
standard to evaluate the relative expression levels of target genes.ombination on different pancreas cancer cell lines
CI75 (±SEM) DRI50 (±SEM) DRI75 (±SEM) r
0.7 (0.0685) 1.5 (0.12) 1.7 (0.1) 0.99
5.4 (0.55) 9.8 (1.12)
0.2 (0.025) 3.3 (0.38) 4.7 (0.36) 0.98
13.1 (1.12) 35 (2.78)
0.5 (0.08) 3.1 (0.189) 3.1 (0.26) 0.97
3.8 (0.25) 5.5 (0.59)
0.4 (0.036) 8.9 (0.96) 8.6 (0.96) 0.95
1.1 (0.25) 3.1 (0.42)
molar ratio of the two agents was used. Combination index (CI) values of b1, 1,
ate experiments performed in quadruplicates) represent the order of magnitude
experiments performed in quadruplicates) represent the assessment of synergy
ecorded.
Table 2
Treatments of human pancreatic tumours in nude mice with TSA (0.25 mg/kg) and GEM (2.5 mg/kg) biweekly for 4 weeks






No. of dead mice/
No. of total mice
Control 5.74±0.8 100±29 24.4±1.0 0/5
TSA (0.25 mg/kg) 6.34±0.5 110±17 24.4±0.7 0/5
GEM (2.5 mg/kg) 5.98±0.7 104±28 27.1±1.7 0/5
TSA+GEM 2.98±0.7* 52±26 * 24.9±1.4 0/5
*pb0.05.
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To examine the in vivo cells growth inhibition, T3M4 human pancreatic
cancer cells (5×106 cells for each mice) were s.c. injected into female nude mice
(4 weeks of age, Charles River Laboratories, Italy). One week after cell
inoculation, 5 randomized animals for each experimental group received vehicle
control (DMSO) or TSA or GEM or TSA plus GEM at doses indicated in the
tables by i.p. injection twice weekly for 4 weeks. Doses were chosen in initial
dose-ranging evaluations, on the basis of the absence of any measurable toxicity.Fig. 3. (A) Cell cycle distribution after TSA and/or GEM treatment. T3M4 cells were
analyzed by a flow cytometer after DNA staining with propidium iodide. (B) Induc
analyzed by flow cytometry to determine the percentage of cells displaying annexin
The percentage apoptosis was calculated by subtracting the untreated control values f
T3M4 cells were treated as in (A) and caspase 3 activity was assessed. (D) Effect of T
treated with 0.2 μM TSA and/or 2 μM GEM for 48 h and the percentage of c
dihexyloxacarbocyanine staining. Values are the means±SEM of three independentNone of the treatments produced any toxicity as indicated by lack of change in
body weight (Table 2) and none of the animals developed ulcerating tumours.
No deaths were observed among any of the considered groups of mice. At the
end of the treatments, mice were sacrificed and subcutaneous tumours were
carefully dissected free of the surrounding normal tissue and weighed. Weekly,
tumour volumes and body mass were recorded for each animal. Animals were
sacrificed at the end of the 4-week study period. Palpable tumours were resected,
weighted and immediately snap-frozen in liquid nitrogen. The animal studies
were approved by the Verona University Review Board.treated with 0.2 μMTSA and/or 2 μMGEM for 24 h. Cell cycle distribution was
tion of apoptosis by TSA and/or GEM. T3M4 cells were treated as in (A) and
V+(early apoptosis) or annexin V+/ propidium iodide+ staining (late apoptosis).
rom the treated values. (C) Induction of caspase 3 activity by TSA and/or GEM.
SA and/or GEM on mitochondrial membrane potential (ΔΨm). T3M4 cells were
ells exhibiting reduced ΔΨm was determined by flow cytometry using 3,3-
experiments. **pb0.01; ***pb0.001.
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ANOVA (post hoc Bonferroni) analysis and graphical presentations were
performed by GraphPad Prism version 5. p values less than 0.05, 0.01 or 0.001
were indicated as *, ** or ***, respectively. Data in Fig. 6C were analyzed by
paired t test.3. Results
3.1. TSA and GEM synergistically inhibit proliferation of
human pancreatic adenocarcinoma cell lines in vitro
Dose-dependent curves of cell viability of pancreatic
adenocarcinoma cell lines treated with TSA or GEM areFig. 4. RT-PCR analysis of the BIM mRNA after treatment with TSA and/or GEM an
from T3M4 cells treated with 0.2 μM TSA and/or 2 μM GEM for 8 h. mRNAs of the
[31] are indicated. Primer sequences and PCR conditions are indicated in Materials a
The intensity of bands corresponding to BIM (EL, L, and S) relative to β-actin is show
(C) siRNA. T3M4 cells were transfected with a BIM siRNA SMARTpool in serum/a
TSA (0.2 μM) and/or GEM (2 μM) were added 24 h after transfection and cells wer
crystal violet colorimetric assay. Values are the means±SEM of three independent e
RNA interference. Transfections were carried out as described in Materials and meth
alternative splicing [31] are indicated. Primer sequences and PCR conditions are shshown in Fig. 1. GEM engendered a plateau of survival ranging
from 75% (PANC1) to 25% (T3M4), while TSAwas generally
more active than GEM and did not show a saturating effect. To
test the effect of a combined treatment with TSA and GEM on
cell growth, we performed drug combination studies using a
dedicated software (Calcusyn, see Materials and methods) for
the elaboration of the results. CI/fractional effect curves
showing the CIs versus the fraction of cells affected/killed by
TSA and GEM in combination, for the different cell lines, are
illustrated in Fig. 2. The fractional effect is the % of growth
inhibition given by each combination of the two drugs. This
value was represented on the X axis of the curve, while on the Y
axis CI given by the same combination was reported. When CI
is below 0.8 a synergistic condition was recorded; with CId RNA interference assay. (A) Electrophoretic analysis. Samples were obtained
three BIM isoforms (BIMEL, BIML and BIMS), derived from alternative splicing
nd methods. A representative experiment is shown. (B) Densitometric analysis.
n. Values are the means±SEM of three independent experiments. ***pb0.001.
ntibiotics free medium and 4 h after transfection complete medium was restored.
e further incubated for 48 h. Percentage of cell survival was evaluated using the
xperiments. *pb0.05. (D) RT-PCR analysis of the BIM mRNA expression after
ods. mRNAs of the three BIM isoforms (BIMEL, BIML and BIMS), derived from
own in Table 2. A representative experiment is shown.
Fig. 5. (A) Effect of TSA and/or GEM on ROS production. T3M4 cells were
treated with 0.2 μM TSA and/or 2 μM GEM for 16 h. The 2′,7′-
dichlorofluorescin (DCF) fluorescence intensity, corresponding to the level of
ROS production, was measured by flow cytometry as described in Materials and
methods. Values are the means±SEM of three independent experiments.
***pb0.001. (B) Effect of NAC on cell growth inhibition by GEM. T3M4 cells
were treated with increasing concentrations of GEM in the absence or presence
of NAC (1 mM) for 48 h. Values are the means of triplicate wells from three
independent experiments for each drug concentration. ***pb0.001. Cell
proliferation was determined using the crystal violet colorimetric assay.
Treatment with 1 mM NAC alone did not affect cell growth.
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additivity, respectively, was found.
In synergistic drug combination the CI50s (the combination
index calculated for 50% cell survival by isobologram analysis)
were, at 1:1 molar ratio of both drugs, respectively, 0.8, 0.4, 0.6
and 1.0 for T3M4, PANC1, PC and CFPAC1 cells (Table 1). In
the same experimental conditions the CI75s (the combination
index calculated for 75% cell survival by isobologram analysis)
were, respectively, 0.7, 0.2, 0.5 and 0.4 for T3M4, PANC1, PC
and CFPAC1 cells (Table 1). The analysis of CIs revealed that
TSA and GEM combinations were globally synergistic
(CIsb0.8) in all cell lines but in CFPAC1 where a clear
synergistic effect was observed only when TSA was combined
with GEM at concentrations able to induce 75% growth
inhibition (CI75=0.4) (Fig. 2, Table 1).
Notably, in all cell lines, a 1.5- up to 13.1-fold reduction in the
IC50 of both TSA and GEM (DRI50) was observed in the
combination setting compared with the concentrations of the
drugs used alone (Table 2). Interestingly, the values of r factor
were always between 0.95 and 0.99 suggesting that the data were
statistically significant (Table 1).
3.2. TSA enhances apoptosis but not cell cycle arrest induced
by GEM
The analyses of flow cytometry with annexin V-FITC and
propidium iodide staining and of caspase 3 activity show that
either TSA or GEM gave rise to an apoptotic effect, which
was strongly increased in the presence of both drugs (Fig. 3B
and Fig. 3C). The potentiation of apoptosis occurred on both
late and early phase of programmed cell death. The combined
treatment, on the contrary, did not further increase cell cycle
arrest determined by single drugs (Fig. 3A). Fig. 3D shows
that the percentage of cells presenting a reduced mitochon-
drial membrane potential (ΔΨm) was strongly increased by
TSA and GEM combination as compared to single drugs,
suggesting the involvement of the mitochondrial pathway in
the induction of apoptosis by the drug combination.
3.3. Bim has a role in growth inhibition by TSA and GEM
The Bcl-2 family of proteins plays a critical role in regulating
programmed cell death involving the mitochondrial pathway
[30]. We show here that the combined treatment of T3M4 cells
with TSA and GEM combination significantly increased mRNA
expression of the three BIM isoforms (BIMEL, BIML and BIMS),
derived from alternative splicing [31], compared to single
treatments (Fig. 4A and Fig. 4B).
To verify a direct role of Bim in TSA- and GEM-induced
growth inhibition, we performed proliferation assays in
T3M4 cell line using RNA interference (RNAi) technology
to knock down endogenous BIM. The results shown in Fig.
4C demonstrated that silencing of BIM (see Fig. 4D)
significantly contributed to protect cells (pb0.05) from
growth inhibition by TSA and/or GEM, indicating that
Bim has a role in cell death by both single and combined
drug treatments.3.4. GEM increases oxidative cellular stress
The induction of ROS has been described to increase
mitochondrial membrane permeability, thus promoting apopto-
sis [32]. We analyzed ROS level in T3M4 cells after TSA and/or
GEM treatment. Fig. 5A shows that ROS levels were increased
of approximately 2-fold by GEM, while they were not affected
by TSA and not further increased by the combined treatment.
Depletion of ROS by the free radical scavenger NACwas able to
significantly decrease the level of cell growth inhibition byGEM
(Fig. 5B), indicating that ROS production plays a role in GEM
induced cytotoxic effect. Furthermore, we observed that
treatment of cells with TSA and H2O2 significantly increased
growth inhibition compared to single agent (data not shown).
Taken together these results indicate that ROS production is
involved in the induction of cell growth inhibition by GEM and
may contribute to the synergistic growth inhibition by TSA and
GEM combined treatment.
To further confirm a potential role of the oxidative stress in the
sensitivity of pancreatic adenocarcinoma cells to GEM, we
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lines with their respective basal oxidative stress. Fig. 6 shows that
the cell lines with a lower basal level of ROSwere more resistant to
GEM (Fig. 6A) compared to the less resistant cell lines (Fig. 6B).
3.5. 5′-nucleotidase UMPH type II has a role in growth
inhibition by GEM
To assess whether TSA affects critical molecular mechanisms
generally associated with GEM resistance, we analyzed by RT-Fig. 6. Comparison between intrinsic ROS production and GEM sensitivity in ten pan
relative mean fluorescence (RMF) and the highest IC50 values of GEM. (B) Cell lin
lowest IC50 values of GEM. RMF is the ratio between fluorescence intensity of cells
(DCF) fluorescence intensity corresponding to the cellular ROS level was measured
concentration determining maximal PANC1 cell line growth inhibition. (C) Diagram s
PANC1 cell line growth inhibition. Paired t test of IC50 and RMF values between cPCR the expression levels of the genes for nucleoside transporters
(CNT1, CNT2, CNT3, ENT1, and ENT2), deoxycytidine kinase
(dCK), 5′-nucleotidases (cN-I, cN-II, and UMPH type I and II) I,
cytidine deaminase (CDD), and the two ribonucleotide reductase
subunits (RRM1 and RRM2). The analysis of mRNAs for those
genes showed that the level of UMPH type II mRNAwas down-
regulated after 8 h TSA treatment (Fig. 7A and Fig. 7B), whereas
the levels of the other mRNAs were not affected (not shown).
To assess the role of 5′-nucleotidase UMPH type II on the
sensitization by TSA of GEM-induced cell growth inhibition,creatic adenocarcinoma cell lines. (A) Cell lines showing the lowest values of the
es showing the highest values of the relative mean fluorescence (RMF) and the
treated and untreated (autofluorescence) with DCF. The 2′,7′-dichlorofluorescin
by flow cytometry as described in Materials and methods. #The lowest GEM
howing RMF versus IC50.
#The lowest GEM concentration determining maximal
ell lines shown in A and B: pb0.001.
Fig. 7. RT-PCR analysis of the UMPH type II mRNA expression after treatment with TSA and/or GEM and RNA interference assay. (A) Electrophoretic analysis.
Samples were obtained from T3M4 cells treated with 0.2 μM TSA and/or 2 μM GEM for 8 h. Primer sequences and PCR conditions are indicated in Materials and
methods. A representative experiment is shown. (B) Densitometric analysis. The intensity of UMPH type II band relative to β-actin is shown. Values are the means±
SEM of three independent experiments. ***pb0.001. (C) siRNA. T3M4 cells were transfected with a specific siRNA SMARTpool for UMPH type II in serum/
antibiotics free medium and 4 h after transfection complete medium was restored. GEM (2 μM) was added 24 h after transfection and cells further incubated for 24 h.
Percentage of cell survival was evaluated using the crystal violet colorimetric assay. ***pb0.001. (D) RT-PCR analysis of the UMPH type II mRNA expression after
RNA interference. Transfections were carried out as described inMaterials and methods. Primer sequences and PCR conditions are indicated in Materials and methods.
A representative experiment is shown.
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technology. Following UMPH type II gene silencing, cell
growth inhibition by GEM was significantly increased
(pb0.001) (Fig. 7C and Fig. 7D), strongly suggesting a role
of UMPH type II for the synergistic effect by TSA and GEM.
3.6. TSA and GEM synergistically inhibit growth of human
pancreatic adenocarcinoma cells in vivo
The effect of TSA and/or GEM on growth inhibition of
pancreatic cancer cells in vivo was examined on subcutaneous
xenografts of T3M4 cells in nude mice. As shown in Table 2,
TSA or GEM did not cause any significant suppression of
tumour growth, while the combination of the two drugs
determined a reduction in the mean tumour weight of about
50% compared to control or single drug treatments (Table 2).The same result was obtained using higher doses of drugs, i.e.
1 mg/kg of TSA and/or 25 mg/kg of GEM (data not shown). To
test whether TSA effectively inhibited histone deacetylase
(HDAC) enzymes in the tumour mass, we examined the levels
of H4 histone acetylation in the dissected tumours from mice
untreated or treated with TSA. Fig. 8 shows that TSA treatment
determined only a 3-fold increase of H4 acetylation levels in
vivo, at both concentrations tested, compared to the 18-fold
increase in vitro. On the other hand, GEM alone did not induce
changes in histone acetylation (data not shown).
4. Discussion
In this study, we have evaluated the in vitro and in vivo effects
of TSA and GEM on human pancreatic adenocarcinoma cell
growth. We report that treatment with increasing concentrations
Fig. 8. Western blot analysis of acetylated histone H4. (A) T3M4 cells were treated with 0.2 μM TSA for 4 h in vitro. Nude mice with subcutaneous xenografts of
T3M4 cells were injected with 0.25 mg/kg or 1 mg/kg TSA biweekly for 4 weeks and sacrificed 4 h after the last TSA injection. Protein extracts were obtained as
described in Materials and methods. (B) The fold induction of histone H4 acetylation was measured by densitometric analysis. Mean values±SEM are reported.
***pb0.001.
Fig. 9. Model of activation of the apoptotic cascade by the combined action of
TSA and GEM in pancreatic adenocarcinoma cells.
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having mutations in the p53 gene, determines a plateau of
survival ranging from 75% to 25% compared to untreated cells.
This result suggests a mechanism of drug resistance, which is not
observed with TSA that induces a complete growth inhibition of
cells.
Resistance to the cytotoxic effect of GEM can be related to
multiple mechanisms including alteration of apoptosis regulat-
ing genes [10], alterations in the transport and cellular turnover
of the drug as well as altered expression or sensitivity of enzyme
targets [5–9,33]. p53 mutations, which are very frequent in
pancreatic cancer [11], reduce gemcitabine-induced apoptosis
[10]. We [23] and others [21] have published that TSA induces
apoptosis in p53-negative cancer cells, suggesting that p53
plays a minor role in the cellular effects of TSA. Moreover, our
earlier studies on mitochondrial related apoptotic genes
demonstrate that the proapoptotic gene BIM is significantly
upregulated by TSA, whereas the antiapoptotic BCL-XL and
BCL-W genes are downregulated [24]. Furthermore, it has
been reported that an increased ratio of expression levels of the
proapoptotic genes versus antiapoptotic BCL-2 sensitizes
pancreatic cancer cells to GEM treatment [34–37]. Here, we
demonstrate that GEM further increases TSA induced BIM
mRNA and that BIM silencing significantly reduces growth
inhibition of pancreatic adenocarcinoma cell lines by TSA and/
or GEM, strongly suggesting the involvement of Bim in the cell
death induction by the two drugs. These data are in agreement
with the results of Zhao et al., who have reported that Bim is a
key mediator of the apoptotic process induced by TSA in p53-
null HCT116 stably expressing E2F1 [25].
The generation of free radicals is generally related to the loss
of mitochondrial inner membrane potential and is considered
one of the cytotoxic activities of GEM [14], although the precise
mechanism responsible for such stress remains to be defined. Inour study, we find that GEM induces an approximately 2-fold
increase of intracellular free radicals and that 1 mM of the
radical scavenger NAC is able to rescue, at least in part, the
antiproliferative effect of GEM. Higher concentrations of NAC,
which could further reduce cell growth inhibition by GEM, are
toxic to pancreatic adenocarcinoma cells, as already reported in
other systems [38]. It is known that the increase in ROS stress
can induce various biological responses, including cellular
proliferation, apoptosis, and necrosis [32]. Cancer cells are
known to be metabolically active and under increased oxidative
stress, which makes them highly dependent on antioxidant
enzymes to cope with the stress of ROS [32,39]. It has been
demonstrated that further oxidative stress such as the exposure
of cancer cells to ROS-generating anticancer agents exhausts
the cellular antioxidant capacity and leads to apoptosis probably
by pushing the ROS stress level beyond a threshold [32,39].
1105M. Donadelli et al. / Biochimica et Biophysica Acta 1773 (2007) 1095–1106Consistent with this observation, we have shown a positive
correlation between intrinsic ROS stress and sensitivity to GEM
in 10 pancreatic adenocarcinoma cell lines. Furthermore, we
demonstrate that H2O2 significantly enhances cell growth
inhibition by TSA (data not shown), suggesting that ROS
production by GEM is an important element in the synergistic
inhibition of pancreatic cancer cells by TSA and GEM.
The analysis of the regulation by TSA of critical molecular
mechanisms generally associated with GEM resistance has
shown that only the mRNA of the 5′-nucleotidase UMPH type
II was regulated after TSA treatment. As UMPH type II is
known to prevent the formation of the active forms of GEM [8],
inhibition of UMPH type II by TSA may be another mechanism
by which the two drugs synergistically inhibit pancreatic
adenocarcinoma cell proliferation. Indeed, RNA interference
experiments demonstrate thatUMPH type II silencing sensitizes
T3M4 cells to GEM. These data may support the idea that the
development of new specific inhibitors of this enzyme could
potentiate the antiproliferative effect of GEM.
Our in vitro results are summarised in the model shown in
Fig. 9. Two recent reports have dealt with the effects of the
combination of GEM with two HDAC inhibitors, 4-phenylbu-
tirrate (4-PB) and suberoylanilide acid (SAHA), on the growth
of pancreatic cancer cell lines in vitro [40,41]. These studies
show that 4-PB and SAHA inhibit cell growth at concentrations
much higher than those used for TSA in this paper, either alone
or in combination with GEM. In addition, while 4-PB is shown
to inhibit cellular export that may thus increase the sensitivity to
GEM, SAHA is shown to exert proapoptotic effects by
upregulating p21 and sequestering it in the cytoplasm. Neither
study has analyzed the biochemical pathways shown here to
play a role in cell growth inhibition by TSA/GEM. In addition,
neither study reports in vivo experiments, which in our opinion
strongly contribute to the suggestion that GEM in combination
with HDAC inhibitors may represent a good candidate therapy
for pancreatic cancer. Although we do not exclude the
possibility that the molecular mechanisms described by
Ammerpohl et al. and Arnold et al. [40,41] may also act in
our system, we believe that the activation of the apoptotic
cascade illustrated by the model of Fig. 9, which takes into
account crucial aspects of TSA and GEM activity, may better
explain the synergism between the two molecules.
In vivo experiments have shown that intraperitoneal injection
of either TSA (0.25 mg/kg) or GEM (2.5 mg/kg) into nude mice
that bear a subcutaneous mass of pancreatic adenocarcinoma
cells cannot arrest tumour growth, while combined treatments
can reduce to 50% the tumour mass. We have also observed that
higher doses of GEM (25 mg/kg), comparable to that used in
clinical trials [42,43], are not able to significantly inhibit
pancreatic adenocarcinoma cell growth in vivo and do not
further enhance growth inhibition obtained with the lower doses
of TSA and GEM, when used in combination with higher doses
of TSA (1 mg/kg). This result suggests that low doses of TSA
may sensitize cells to overcome GEM resistance. It is
noteworthy that all the in vivo treatments did not determine
any apparent form of toxicity in vivo, as we did not observe
mice deaths, body weight variations or other apparent toxicity-related features. This result may be ascribed to the fact that
GEM is a well-tolerated chemotherapeutic agent [44] and that
HDAC inhibitors seem to be specifically selective against
tumour cells [17,18] and show a very low toxicity in vivo
[19,20].
In conclusion, the present study describes the molecular
mechanisms underlying the synergistic inhibition of pancreatic
cancer cell growth in vitro by TSA and GEM. Moreover, the
significant in vivo antitumour activity by TSA and GEM,
together with the absence of toxicity, provide a rationale basis
for the development of novel therapies in pancreatic cancer
using the gold standard GEM in combination with an HDAC
inhibitor.
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